TCL Archive ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial. September 8, 2006
TCL Archive FCRF Program Proving Good Basic Research Can Be Supported By NCI With a Contract January 23, 1987
TCL Archive Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients. April 9, 2010
TCL Archive “Leadership Vacuum: At NCI Allows NIH To Look At Reorganization, Varmus Says November 4, 1994
TCL Archive “Mind Boggling” Results Reported In Trials Using 3-Drug Combination For Breast Cancer October 10, 1975
